NOCTRAN 10mg Price

Overview

Welcome to Dwaey, specifically on NOCTRAN 10mg page.
This medicine contains an important and useful components, as it consists of
Clorazepate dipotassium, Acepromoazine (as acid maleate), Acepromethazine (as acid maleate)is available in the market in concentration

Name

Tocilizumab

Precaution

Before starting **Tocilizumab**, it is essential for patients to consult their healthcare provider, particularly if they have the following conditions: - **Infections**: Tocilizumab is an **immunosuppressive agent**. It may increase the risk of infections, including serious ones like **tuberculosis**, **bacterial**, **fungal**, or **viral infections**. Ensure that any active infection is treated before beginning therapy. Patients should be tested for **latent tuberculosis** prior to starting treatment. - **Liver Impairment**: Tocilizumab can cause liver enzyme abnormalities and **hepatotoxicity**. Liver function tests should be monitored regularly, especially for patients with pre-existing liver conditions. - **Gastrointestinal Perforation**: Use with caution in patients with a history of **intestinal perforations** or conditions that predispose to it (such as diverticulitis). - **Risk of Cytopenias**: Tocilizumab can cause **decreased blood cell counts**, including **neutropenia**, **thrombocytopenia**, and **anemia**. Regular blood tests are required to monitor blood cell levels. - **Cardiovascular Concerns**: Patients with **heart failure** or those at risk for cardiovascular events should be closely monitored, as Tocilizumab can cause **elevated cholesterol** and **lipid levels**. - **Vaccination**: Live vaccines should be avoided during treatment, as Tocilizumab may reduce the effectiveness of vaccines. Patients should be up-to-date with their vaccinations before starting therapy.

Indication

Tocilizumab is an **interleukin-6 (IL-6) receptor antagonist** used in the treatment of several inflammatory conditions: - **Rheumatoid Arthritis**: It is commonly prescribed for moderate-to-severe **rheumatoid arthritis** in adult patients who have not responded adequately to other disease-modifying antirheumatic drugs (DMARDs). - **Systemic Juvenile Idiopathic Arthritis (SJIA)**: Tocilizumab is indicated for the treatment of **systemic juvenile idiopathic arthritis** in pediatric patients. - **Giant Cell Arteritis (GCA)**: This drug is approved for the treatment of **giant cell arteritis**, a condition that causes inflammation of blood vessels. - **Cytokine Release Syndrome (CRS)**: Tocilizumab is used for the treatment of severe or life-threatening **cytokine release syndrome** (CRS) induced by **chimeric antigen receptor T-cell (CAR-T)** therapy, which occurs due to excessive activation of immune cells. - **COVID-19**: In certain severe cases of **COVID-19** with systemic inflammation and cytokine release syndrome, Tocilizumab is used to reduce inflammation and prevent organ damage, although it is administered under strict medical supervision and guidance.

Contra indication

Tocilizumab is contraindicated in certain conditions: - **Active Infections**: Patients with active or serious infections, such as tuberculosis, bacterial, viral, or fungal infections, should not use Tocilizumab. It may worsen the infection. - **Hypersensitivity**: Patients with a known hypersensitivity or allergic reaction to Tocilizumab or any of its components should not use this medication. - **Liver Disease**: Tocilizumab is contraindicated in patients with **severe hepatic impairment** or active liver disease, due to the risk of **hepatotoxicity**. - **Neutropenia**: Tocilizumab should not be used in patients with a **history of neutropenia** or **low white blood cell count** (absolute neutrophil count < 2000 cells/μL). - **Pregnancy**: Tocilizumab is not recommended during pregnancy, especially in the **third trimester**, due to potential harm to the fetus.

Side Effect

Tocilizumab may cause both common and severe side effects: - **Common Side Effects**: - **Headache** or **dizziness**. - **Upper respiratory tract infections**, such as **sinusitis**, **pharyngitis**, or **nasopharyngitis**. - **Hypertension** (high blood pressure). - **Nausea**, **vomiting**, or **diarrhea**. - **Injection site reactions**, including pain, swelling, or redness. - **Fatigue** or **malaise**. - **Serious Side Effects**: - **Severe Infections**: Because of its immunosuppressive effects, Tocilizumab can increase the risk of serious infections like **tuberculosis**, **fungal infections**, and **bacterial infections**. - **Liver Damage**: Elevated liver enzymes (AST, ALT) may indicate **hepatotoxicity**. Serious liver injury, including **liver failure**, has been reported. - **Cytopenias**: Tocilizumab can cause **low white blood cell counts** (neutropenia), **low red blood cell counts** (anemia), or **low platelet counts** (thrombocytopenia). - **Gastrointestinal Perforation**: Rare cases of gastrointestinal perforation (holes in the stomach or intestines) have been reported, especially in patients with a history of diverticulitis. - **Elevated Cholesterol and Lipids**: Tocilizumab can cause elevated levels of **LDL cholesterol** and **triglycerides**. - **Cardiovascular Risk**: Long-term use of Tocilizumab may increase the risk of **heart failure** or exacerbate pre-existing cardiovascular conditions.

Pregnancy Category ID

3

Mode of Action

Tocilizumab is a **monoclonal antibody** that works by blocking the action of **interleukin-6 (IL-6)**, a cytokine involved in the inflammatory response. IL-6 plays a key role in the development of many autoimmune and inflammatory diseases, including **rheumatoid arthritis** and **juvenile idiopathic arthritis**. By inhibiting the **IL-6 receptor**, Tocilizumab reduces inflammation, pain, and other symptoms associated with these conditions. It also helps in modulating the immune system’s overreaction during conditions like **cytokine release syndrome** in cancer therapies or **COVID-19**.

Interaction

Several drug interactions may occur with Tocilizumab, which can affect its efficacy or safety: - **Immunosuppressive Drugs**: Combining Tocilizumab with other immunosuppressive drugs (e.g., **methotrexate**, **biologics**) may increase the risk of infections. Patients should be monitored closely for signs of infection. - **CYP450 Inhibitors and Inducers**: Tocilizumab is metabolized by liver enzymes, particularly **CYP450 enzymes**. Drugs that inhibit or induce these enzymes (e.g., **rifampin**, **carbamazepine**) may alter the levels of Tocilizumab in the blood. Careful monitoring is required if these drugs are used concurrently. - **Statins**: Tocilizumab can increase **lipid levels**, and combining it with **statins** (e.g., **atorvastatin**) may require dose adjustments of the statin to manage cholesterol levels. - **Live Vaccines**: Since Tocilizumab suppresses the immune system, live vaccines should be avoided during treatment. It is recommended to receive vaccines at least **4 weeks** prior to starting therapy. - **Methotrexate**: When combined with methotrexate, Tocilizumab can increase the risk of **liver toxicity**. Close monitoring of liver enzymes is necessary during concurrent use.

Pregnancy Category Note

Information not available

Adult Dose

The dosing of Tocilizumab depends on the condition being treated: - **Rheumatoid Arthritis**: The typical dose is **8 mg/kg** administered every **4 weeks** as an intravenous infusion. - **Systemic Juvenile Idiopathic Arthritis**: The dose for children and adults varies, typically starting at **8 mg/kg** every **4 weeks**. - **Giant Cell Arteritis**: The recommended dose is **162 mg** once a week via subcutaneous injection. - **Cytokine Release Syndrome**: For **CRS** due to CAR-T cell therapy, the initial dose is typically **8 mg/kg** intravenously, followed by additional doses as needed based on clinical response. - **COVID-19**: Dosing for COVID-19 is typically **8 mg/kg** as a one-time intravenous infusion, followed by further treatment as determined by the healthcare provider.

Child Dose

For pediatric patients with **Systemic Juvenile Idiopathic Arthritis (SJIA)**: - The recommended dose is **12 mg/kg** for children weighing less than 30 kg or **8 mg/kg** for children weighing 30 kg or more, administered every **4 weeks** intravenously. - For **Cytokine Release Syndrome (CRS)**, the dosing is determined by the severity and weight of the child, usually starting at **8 mg/kg** intravenously. Subsequent doses depend on the clinical situation. As always, it's critical to consult with a healthcare provider before starting or adjusting the dose of Tocilizumab, as individual responses and needs may vary.

Renal Dose

In patients with renal impairment, **Tocilizumab** does not require any adjustment in dose. However, patients with **severe kidney disease** should be monitored closely for any adverse effects, as **immunosuppressive drugs** may exacerbate existing renal conditions.

Administration

Information not available